CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome

Table 3

Serum concentration and functional activity of complement proteins in thrombotic APS patients with specific laboratory and clinical abnormalities.

Parameter		C3 (mg/dL)	C4 (mg/dL)	FB (mg/dL)	CH100 (U/mL)
aCL titer	High	87.6 ± 21.1	14.1 ± 7.7	30 ± 10.1	35.2 ± 23.7
	Medium	108.3 ± 28.6	20.7 ± 8.8	33.5 ± 7.3	48 ± 13.1
	P	0.027	0.026	0.32	0.31
ANA	Positive	84.3 ± 27.5	16.1 ± 11.9	27.3 ± 12.6	35.4 ± 24.8
	Negative	103.2 ± 24.2	17.13 ± 7.1	33.9 ± 7.7	37.8 ± 21.22
	P	0.54	0.76	0.09	0.85
Anti-DNA	Positive	86.6 ± 22.2	11.9 ± 6.1	34 ± 5	24.8 ± 3.8
	Negative	100 ± 26.9	18.1 ± 8.6	31.6 ± 10.3	41.8 ± 24.1
	P	0.26	0.08	0.62	0.19
Thrombocytopenia	Yes	90.9 ± 28.6	14.95 ± 8.3	25.6 ± 13.8	15.3 ± 13.6
	No	99.4 ± 25.9	17.4 ± 8.6	33.5 ± 7.9	42.8 ± 19.8
	P	0.46	0.48	0.07	0.046
Risk factors for thrombosis	Yes	97.5 ± 27.9	17.1 ± 8.9	33.4 ± 7.9	31.7 ± 24
	No	106 ± 28.2	19.3 ± 5.5	32.9 ± 8.9	47.0 ± 15.6
	P	0.526	0.55	0.89	0.42

High-titer aCL, IgG, or IgM anticardiolipin antibodies >80 U/mL. High-titer antinuclear antibodies (ANA) >1/160. High anti-DNA >20 IU/mL. Thrombocytopenia, platelet count < 100,000/μL. Risk factors include arterial hypertension, portal hypertension, atrial fibrillation, dyslipidemia, homocysteinemia, hypergammaglobulinemia, and smoking.